Core Insights - Pacific Software Inc. has successfully completed the acquisition of all outstanding shares of 10763942 Canada Inc., which operates as PurMinds NeuroPharma, and the common stock is now quoted on the OTC market [1] - PurMinds has announced a global partnership with SpectroChip Inc. to enhance its precision neuromedicine strategy [2][3] Company Developments - The management team of PurMinds has taken leadership roles post-acquisition and is considering a name change to PurMinds Enterprises, pending FINRA approval [1] - The partnership with SpectroChip aims to integrate PurMinds' expertise in biomarker discovery and multi-omics studies with SpectroChip's photonic chip-based diagnostic technology [3] Strategic Goals - The collaboration is expected to create a new revenue stream, with revenue generation anticipated to begin in 2026 [4] - PurMinds is focused on building a predictive, preventive, personalized, and participatory healthcare ecosystem through this partnership [4] Product and Technology Integration - The partnership will develop rapid, intelligent, and cost-effective point-of-care testing solutions, providing hospital-grade diagnostics at the patient's bedside [3] - SpectroChip's diagnostic platform integrates various technologies into a compact chip, offering laboratory-grade precision and cloud-based data integration [7] Clinical Pipeline and Innovation - PurMinds is developing innovative solutions for neurological and psychiatric disorders, including psychoactive compounds and proprietary non-hallucinogenic small molecules [6] - The company has established unique intellectual property assets and partnerships with leading research institutions to support its clinical programs [6]